Dataset Information

Institut Gustav Roussy, Paris

ABSTRACT: Organisation EGAO00000000253

PROVIDER: EGAO00000000253 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Publications

Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Taylor Kathryn R KR Mackay Alan A Truffaux Nathalène N Butterfield Yaron Y Morozova Olena O Philippe Cathy C Castel David D Grasso Catherine S CS Vinci Maria M Carvalho Diana D Carcaboso Angel M AM de Torres Carmen C Cruz Ofelia O Mora Jaume J Entz-Werle Natacha N Ingram Wendy J WJ Monje Michelle M Hargrave Darren D Bullock Alex N AN Puget Stéphanie S Yip Stephen S Jones Chris C Grill Jacques J

Nature genetics 20140406 5

Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clinical outcome. The median survival time is 9-12 months, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clinical trials in children with these tumors. We report the identification of recurrent activating mutations in ...[more]

PMID: 24705252

Similar Datasets

Project description:BACKGROUND:Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). METHODS:An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. RESULTS:Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4?months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N?=?41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (>?70) were the two factors associated with a higher risk of intensive care unit admission and/or death. CONCLUSIONS:This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.

Dataset Information

Institut Gustav Roussy, Paris

Publications

Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets